Background Cognate immunity against neoplastic cells depends on a balance between
effector T cells and regulatory T (Treg) cells. Treg cells prevent immune attack against …

Background We previously found that administration of an interleukin 2/diphtheria toxin
conjugate (DAB/IL2; Denileukin Diftitox; ONTAK) to stage IV melanoma patients depleted …

Purpose Peripheral blood–derived antigen-specific cytotoxic T cells (CTLs) provide a readily
available source of effector cells that can be administered with minimal toxicity in an …

Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive
cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous …

Background Adoptive cell therapy with peripheral blood T cells expressing transgenic T-cell
receptors (TCRs) is an innovative therapeutic approach for solid malignancies. We …

We determined how CD8+ melanoma tumor–infiltrating lymphocytes (TILs) isolated from two
distinct phases of expansion in preparation for adoptive T cell therapy respond to melanoma …

Tumor antigen–specific T cells are found within melanomas, yet tumors continue to grow.
Although the tumor microenvironment is thought to influence the suppression of tumor …

Background The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated
robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) …

It is not known if immune response to T cell–defined human histocompatibility leukocyte
antigen (HLA) class I–restricted melanoma antigens leads to an expanded peripheral pool …

Recurrent solid malignancies are often refractory to standard therapies. Although adoptive T
cell transfer may benefit select individuals, the majority of patients succumb to their disease …